Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Phase 1, Exploratory Study Investigating the Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2017
At a glance
- Drugs HTL 9936 (Primary)
- Indications Cognition disorders
- Focus Therapeutic Use
- Sponsors Heptares Therapeutics
- 10 Jun 2017 Biomarkers information updated
- 02 Feb 2017 Status changed from recruiting to completed.
- 09 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.